{"altmetric_id":6011449,"counts":{"readers":{"mendeley":13,"citeulike":0,"connotea":0},"total":{"posts_count":11},"twitter":{"unique_users_count":5,"unique_users":["clinthe","BibliotecaHUVH","una_tal_maria","idiapjordigol","SalutMedia"],"posts_count":10},"facebook":{"unique_users_count":1,"unique_users":["116510845078689"],"posts_count":1}},"selected_quotes":["Article investigadors@idiapjordigol sobre f\u00e0rmacs per la fibril\u00b7laci\u00f3 auricular.","Article Clinical Therapeutics d'investigadors","How heart rate\/rhythm pharmacological issues are managed in non-valvular #atrialfibrillation patients? #heart #rate","Rate and Rhythm Control in Nonvalvular Atrial Fibrillation. Clinical Therapeutics @clinthe @idiapjordigol"],"citation":{"abstract":"The purpose of this study is to describe the pharmacologic management of rate and rhythm and assess which factors are associated with the prescription of these drugs in patients with nonvalvular atrial fibrillation (AF) from the Effectiveness, Safety, and Costs in Atrial Fibrillation study.\nThis retrospective, cross-sectional study describes the pharmacologic rate and rhythm control management strategies adopted during 2012 in all patients diagnosed as having nonvalvular AF in 2007 to 2011. The data source is the Information System for the Improvement of Research in Primary Care database, which is based on primary care electronic health records. To answer the study objectives, 3 multivariate regression models to assess the independent factors associated with the prescription of these drugs were conducted for 2012. The rate and rhythm control drugs assessed were \u03b2-blockers, nondihydropyridine calcium channel blockers, antiarrhythmic agents, and digoxin.\nA total of 21,304 patients were diagnosed as having nonvalvular AF; 11,638 (54.6%) had at least one heart rate measure during 2012. Of them, 7777 (66.8%) received one or more rate and\/or rhythm control drugs during 2012. Most patients (5751 [73.9%] of 7777) received only one drug for rate and\/or rhythm control. Rate control agents were the most frequently used in 2012, with \u03b2-blockers the most prescribed group (4091 patients [52.6%]). A variety of different variables were associated with the prescription of rate and\/or rhythm control drugs in the multivariate regression models.\nThe most used pharmacologic treatment of rate and rhythm control in our AF population is \u03b2-blockers, indicating that a rate control strategy is preferred in our setting, as widely recommended.","altmetric_jid":"4f6fa4ea3cf058f61000257d","authors":["Maria Giner-Soriano","Albert Roso-Llorach","Cristina Vedia Urgell","Aina Casellas","Ignacio Ferreira-Gonz\u00e1lez","Dolors Capell\u00e0","Rosa Morros"],"doi":"10.1016\/j.clinthera.2016.02.002","endpage":"873","first_seen_on":"2016-02-26T23:54:02+00:00","funders":["niehs"],"issns":["0149-2918","1879-114X"],"issue":"4","journal":"Clinical Therapeutics","last_mentioned_on":1472059603,"links":["http:\/\/www.clinicaltherapeutics.com\/article\/S0149-2918(16)30053-4\/abstract?rss=yes&utm_source=twitterfeed&utm_medium=twitter","http:\/\/www.sciencedirect.com\/science\/article\/pii\/S0149291816300534","http:\/\/www.clinicaltherapeutics.com\/article\/S0149-2918%2816%2930053-4\/abstract","http:\/\/www.clinicaltherapeutics.com\/article\/S0149-2918(16)30053-4\/abstract","https:\/\/secure.jbs.elsevierhealth.com\/action\/getSharedSiteSession?redirect=http:\/\/www.clinicaltherapeutics.com\/article\/S0149-2918(16)30053-4\/abstract&rc=0&code=clithe-site"],"pdf_url":"http:\/\/www.clinicaltherapeutics.com\/article\/S0149291816300534\/pdf","pmid":"26926321","pubdate":"2016-02-26T00:00:00+00:00","publisher":"Elsevier","publisher_subjects":[{"name":"Pharmacology And Pharmaceutical Sciences","scheme":"era"}],"scopus_subjects":["Health Sciences","Medicine","Life Sciences","Pharmacology, Toxicology and Pharmaceutics"],"startpage":"863","subjects":["drugtherapy"],"title":"Drug Therapy for Rate and Rhythm Control in Nonvalvular Atrial Fibrillation: A Cross-sectional Study With Electronic Health Records in a Primary Care Cohort","type":"article","volume":"38","mendeley_url":"http:\/\/www.mendeley.com\/research\/drug-therapy-rate-rhythm-control-nonvalvular-atrial-fibrillation-crosssectional-study-electronic-hea"},"altmetric_score":{"score":3.75,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":3.75},"context_for_score":{"all":{"total_number_of_other_articles":8272014,"mean":6.980828736602,"rank":1905241,"this_scored_higher_than_pct":76,"this_scored_higher_than":6351632,"rank_type":"exact","sample_size":8272014,"percentile":76},"similar_age_3m":{"total_number_of_other_articles":288531,"mean":10.829721484767,"rank":81699,"this_scored_higher_than_pct":71,"this_scored_higher_than":206124,"rank_type":"exact","sample_size":288531,"percentile":71},"this_journal":{"total_number_of_other_articles":1828,"mean":3.9510399562124,"rank":264,"this_scored_higher_than_pct":85,"this_scored_higher_than":1562,"rank_type":"exact","sample_size":1828,"percentile":85},"similar_age_this_journal_3m":{"total_number_of_other_articles":79,"mean":2.399358974359,"rank":12,"this_scored_higher_than_pct":84,"this_scored_higher_than":67,"rank_type":"exact","sample_size":79,"percentile":84}}},"demographics":{"poster_types":{"member_of_the_public":4,"practitioner":1},"users":{"twitter":{"cohorts":{"Members of the public":4,"Practitioners (doctors, other healthcare professionals)":1}},"mendeley":{"by_status":{"Professor > Associate Professor":2,"Librarian":1,"Researcher":4,"Student  > Ph. D. Student":3,"Other":1,"Professor":2},"by_discipline":{"Medicine and Dentistry":6,"Social Sciences":1,"Earth and Planetary Sciences":1,"Nursing and Health Professions":1,"Mathematics":1,"Unspecified":1,"Pharmacology, Toxicology and Pharmaceutical Science":2}}},"geo":{"twitter":{"US":1,"ES":4},"mendeley":{"GB":1}}},"posts":{"twitter":[{"url":"http:\/\/twitter.com\/clinthe\/statuses\/703357753792704512","license":"gnip","citation_ids":[6011449],"posted_on":"2016-02-26T23:15:30+00:00","author":{"name":"clinicaltherapeutics","url":"http:\/\/www.clinicaltherapeutics.com\/home","image":"https:\/\/pbs.twimg.com\/profile_images\/901963433616306176\/3626f_ib_normal.jpg","description":"Elsevier peer-reviewed rapid dissemination of reliable and evolving evidence derived from clinical pharmacology and other therapeutic approaches.","id_on_source":"clinthe","tweeter_id":"372351408","geo":{"lt":39.76,"ln":-98.5,"country":"US"},"followers":1068},"tweet_id":"703357753792704512"},{"url":"http:\/\/twitter.com\/BibliotecaHUVH\/statuses\/704249867233837056","license":"gnip","citation_ids":[6011449],"posted_on":"2016-02-29T10:20:27+00:00","author":{"name":"BibliotecaHUVH. ICS","url":"http:\/\/www.vhebron.net","image":"https:\/\/pbs.twimg.com\/profile_images\/875677660990636032\/7po0FDW5_normal.jpg","description":"Biblioteca Digital de l\u2019Hospital Universitari Vall d\u2019Hebron. Institut Catal\u00e0 de la Salut. Departament de Salut. Generalitat de Catalunya","id_on_source":"BibliotecaHUVH","tweeter_id":"124130301","geo":{"lt":41.38879,"ln":2.15899,"country":"ES"},"followers":2027},"tweet_id":"704249867233837056"},{"url":"http:\/\/twitter.com\/una_tal_maria\/statuses\/704281276870688768","license":"gnip","citation_ids":[6011449],"posted_on":"2016-02-29T12:25:15+00:00","author":{"name":"maria","url":"http:\/\/orcid.org\/0000-0003-3750-9233","image":"https:\/\/pbs.twimg.com\/profile_images\/496257883601141760\/L6WRHZ4C_normal.jpeg","description":"PharmD, PhD, clinical pharmacist. #pharmacoepidemiology #research #idiapjordigol Perqu\u00e8 hi haur\u00e0 un dia que no podrem m\u00e9s i llavors ho podrem tot","id_on_source":"una_tal_maria","tweeter_id":"534516512","geo":{"lt":39.5,"ln":-0.75,"country":"ES"},"followers":511},"tweet_id":"704281276870688768"},{"url":"http:\/\/twitter.com\/clinthe\/statuses\/706894887438983168","license":"gnip","citation_ids":[6011449],"posted_on":"2016-03-07T17:30:49+00:00","author":{"name":"clinicaltherapeutics","url":"http:\/\/www.clinicaltherapeutics.com\/home","image":"https:\/\/pbs.twimg.com\/profile_images\/901963433616306176\/3626f_ib_normal.jpg","description":"Elsevier peer-reviewed rapid dissemination of reliable and evolving evidence derived from clinical pharmacology and other therapeutic approaches.","id_on_source":"clinthe","tweeter_id":"372351408","geo":{"lt":39.76,"ln":-98.5,"country":"US"},"followers":1068},"tweet_id":"706894887438983168"},{"url":"http:\/\/twitter.com\/idiapjordigol\/statuses\/710048813893984256","license":"gnip","citation_ids":[6011449],"posted_on":"2016-03-16T10:23:23+00:00","author":{"name":"IDIAP Jordi Gol","url":"http:\/\/www.idiapjgol.org\/","image":"https:\/\/pbs.twimg.com\/profile_images\/778159921535782916\/cUJ2QQP4_normal.jpg","description":"Institut Universitari d\u2019Investigaci\u00f3 en #atencioprimaria. Fem #recerca en primer nivell assistencial de #salut. University Institute in #primarycare #research","id_on_source":"idiapjordigol","tweeter_id":"551667545","geo":{"lt":41.82046,"ln":1.86768,"country":"ES"},"followers":1102},"tweet_id":"710048813893984256"},{"url":"http:\/\/twitter.com\/SalutMedia\/statuses\/710048813772308481","license":"gnip","citation_ids":[6011449],"posted_on":"2016-03-16T10:23:23+00:00","author":{"name":"SalutMedia not\u00edcies","image":"https:\/\/pbs.twimg.com\/profile_images\/2652377372\/cf3ab3cffb16ba564db45d454aeb3031_normal.png","description":"Not\u00edcies de salut. \nAtenci\u00f3 Prim\u00e0ria i serveis sanitaris en general.","id_on_source":"SalutMedia","tweeter_id":"496232355","geo":{"lt":41.38879,"ln":2.15899,"country":"ES"},"followers":762},"tweet_id":"710048813772308481"},{"url":"http:\/\/twitter.com\/una_tal_maria\/statuses\/715633807156776960","license":"gnip","rt":["idiapjordigol"],"citation_ids":[6011449],"posted_on":"2016-03-31T20:16:10+00:00","author":{"name":"maria","url":"http:\/\/orcid.org\/0000-0003-3750-9233","image":"https:\/\/pbs.twimg.com\/profile_images\/496257883601141760\/L6WRHZ4C_normal.jpeg","description":"PharmD, PhD, clinical pharmacist. #pharmacoepidemiology #research #idiapjordigol Perqu\u00e8 hi haur\u00e0 un dia que no podrem m\u00e9s i llavors ho podrem tot","id_on_source":"una_tal_maria","tweeter_id":"534516512","geo":{"lt":39.5,"ln":-0.75,"country":"ES"},"followers":511},"tweet_id":"715633807156776960"},{"url":"http:\/\/twitter.com\/idiapjordigol\/statuses\/715798482393702402","license":"gnip","citation_ids":[6011449],"posted_on":"2016-04-01T07:10:31+00:00","author":{"name":"IDIAP Jordi Gol","url":"http:\/\/www.idiapjgol.org\/","image":"https:\/\/pbs.twimg.com\/profile_images\/778159921535782916\/cUJ2QQP4_normal.jpg","description":"Institut Universitari d\u2019Investigaci\u00f3 en #atencioprimaria. Fem #recerca en primer nivell assistencial de #salut. University Institute in #primarycare #research","id_on_source":"idiapjordigol","tweeter_id":"551667545","geo":{"lt":41.82046,"ln":1.86768,"country":"ES"},"followers":1102},"tweet_id":"715798482393702402"},{"url":"http:\/\/twitter.com\/SalutMedia\/statuses\/715798482402074624","license":"gnip","citation_ids":[6011449],"posted_on":"2016-04-01T07:10:31+00:00","author":{"name":"SalutMedia not\u00edcies","image":"https:\/\/pbs.twimg.com\/profile_images\/2652377372\/cf3ab3cffb16ba564db45d454aeb3031_normal.png","description":"Not\u00edcies de salut. \nAtenci\u00f3 Prim\u00e0ria i serveis sanitaris en general.","id_on_source":"SalutMedia","tweeter_id":"496232355","geo":{"lt":41.38879,"ln":2.15899,"country":"ES"},"followers":762},"tweet_id":"715798482402074624"},{"url":"http:\/\/twitter.com\/clinthe\/statuses\/768499793488257024","license":"gnip","citation_ids":[6011449],"posted_on":"2016-08-24T17:26:43+00:00","author":{"name":"clinicaltherapeutics","url":"http:\/\/www.clinicaltherapeutics.com\/home","image":"https:\/\/pbs.twimg.com\/profile_images\/901963433616306176\/3626f_ib_normal.jpg","description":"Elsevier peer-reviewed rapid dissemination of reliable and evolving evidence derived from clinical pharmacology and other therapeutic approaches.","id_on_source":"clinthe","tweeter_id":"372351408","geo":{"lt":39.76,"ln":-98.5,"country":"US"},"followers":1068},"tweet_id":"768499793488257024"}],"facebook":[{"title":"t.co","url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=1050122098384221&id=116510845078689","license":"public","citation_ids":[6011449],"posted_on":"2016-02-29T10:20:40+00:00","summary":"#hvhebron #cardio participa Drug Therapy for Rate and Rhythm Control in Nonvalvular Atrial Fibrillation: A Cross https:\/\/t.co\/lHYgBouSII","author":{"name":"Biblioteca Digital de l'Hospital Universitari Vall d'Hebron. ICS","url":"https:\/\/www.facebook.com\/116510845078689","facebook_wall_name":"Biblioteca Digital de l'Hospital Universitari Vall d'Hebron. ICS","image":"https:\/\/graph.facebook.com\/116510845078689\/picture","id_on_source":"116510845078689"}}]}}